Pharmacodynamics. Riboxin is an anabolic drug, has antihypoxic and antiarrhythmic effect. It is a precursor of ATP, is directly involved in the metabolism of glucose and contributes to the activation of metabolism in hypoxic conditions and in the absence of ATP. The drug activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration and contributes to the activation of xanthine dehydrogenase. Riboxin has a positive effect on the metabolism in the myocardium, in particular, increases the energy balance of cells, stimulates the synthesis of nucleotides, and increases the activity of a number of Krebs cycle enzymes. The drug normalizes the contractile activity of the myocardium and contributes to a more complete relaxation of the myocardium in diastole due to the ability to bind calcium ions penetrating into the cells during their excitation, activates tissue regeneration (especially the myocardium and mucous membrane of the digestive tract).
Pharmacokinetics. When a / in the introduction of riboxin is rapidly distributed in the tissues, metabolized in the liver, where it is completely utilized in the biochemical reactions of the body. Escreted mainly with urine.
Comprehensive treatment of coronary artery disease (condition after myocardial infarction, angina), cardiac rhythm disturbance caused by the use of cardiac glycosides, treatment of cardiomyopathy of various genesis, myocarditis (against the background of physical overload), liver disease (hepatitis, liver cirrhosis, fatty degeneration of the liver), urokoproporfiria; leukopenia prevention during irradiation. As a means of improving visual function, Riboxin is used for open-angle glaucoma with normalized (with antihypertensive drugs) intraocular pressure.
Pills. Inside before meals at a daily dose of